1-Year Follow up to the 1473-IMIQ Study

Graceway Pharmaceuticals, LLC84 enrolled

Overview

This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Keratosis

Interventions

Imiquimod 5% creamDRUG

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subject had to participate in the 1473-IMIQ Study AND have had 100% clearance of AK lesions Exclusion Criteria: * Did not use any topical preparations in the previous treatment area within 24-hours of the scheduled visit.

Locations (1)

Unnamed facility

Little Rock, Arkansas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.